2025
Protection against Amyloid‑β Aggregation and Ferroptosis/Oxytosis Toxicity by Arylpyrazolones: Alzheimer’s Disease Therapeutics
Soares P, Rahaman M, Maher P, Silverman R. Protection against Amyloid‑β Aggregation and Ferroptosis/Oxytosis Toxicity by Arylpyrazolones: Alzheimer’s Disease Therapeutics. ACS Medicinal Chemistry Letters 2025, 16: 294-300. PMID: 39967645, PMCID: PMC11831554, DOI: 10.1021/acsmedchemlett.4c00530.Peer-Reviewed Original Research
2024
Integrating the gut microbiome and pharmacology
Verdegaal A, Goodman A. Integrating the gut microbiome and pharmacology. Science Translational Medicine 2024, 16: eadg8357. PMID: 38295186, PMCID: PMC12121898, DOI: 10.1126/scitranslmed.adg8357.Peer-Reviewed Original Research
2023
Advantages and Disadvantages of Nutraceuticals
Rajalakshmi R, Melians M, Pon F, Cosio D, Buvarahamurthy V, Jayakumar A, Paidas M. Advantages and Disadvantages of Nutraceuticals. Nutritional Neurosciences 2023, 245-286. DOI: 10.1007/978-981-99-0677-2_15.Peer-Reviewed Original ResearchEfficacy of nutraceuticalsHeavy metalsLimitations of nutraceuticalsPoor bioavailabilityDrug bioavailabilityBioavailabilityNutraceutical marketLack of experimental evidencePrevent chronic diseasesContaminationPatient health issuesSide effectsHealth professionalsNutrientsNutraceuticalsSide effect profileMetalChronic diseasesRaw materialsHealth issuesToxicityToxic side effectsCompoundsDrug-drug interactionsBlood-brain barrier
2021
Phosphorus bioaccessibility measured in four amino acid–based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice
Chande S, Dijk F, Fetene J, Yannicelli S, Carpenter TO, van Helvoort A, Bergwitz C. Phosphorus bioaccessibility measured in four amino acid–based formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice. Nutrition 2021, 89: 111291. PMID: 34111672, PMCID: PMC8588148, DOI: 10.1016/j.nut.2021.111291.Peer-Reviewed Original ResearchConceptsPhosphorus bioavailabilityAmino acid-based formulaProton pump inhibitorsDigestion modelBioavailability analysisPlasma phosphorus levelsLow phosphorus dietDigestion conditionsBioaccessibilityBioavailabilityStomach acidificationDigestive conditionsIntact fibroblast growth factor 23Phosphorus dietFibroblast growth factor 23Stomach pH.Intact parathyroid hormoneAcid-suppressive medicationsDihydroxy vitamin DGrowth factor 23Phosphorus levelsPhosphorus bioaccessibilityAcidificationPhosphorusIntact fibroblast growth factorTargeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides
Dharmaratne NU, Kaplan AR, Glazer PM. Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides. Cells 2021, 10: 541. PMID: 33806273, PMCID: PMC8000199, DOI: 10.3390/cells10030541.Peer-Reviewed Original ResearchConceptsNucleic acid analoguesPH-sensitive peptideLow insertion peptideAcidic tumor microenvironmentPoor bioavailabilityInsertion peptideFluorescent dyeHigh toxicitySelective deliveryAcid analoguesSmall molecule inhibitorsNanoparticlesCancer therapeuticsMolecule inhibitorsDyePeptidesReview articleAcidityPHLIPPromising toolBioavailabilityAnaloguesDeliveryHypoxic tumor microenvironment
2020
Bronchopulmonary dysplasia is associated with reduced oral nitrate reductase activity in extremely preterm infants
Gentle S, Ahmed K, Yi N, Morrow C, Ambalavanan N, Lal C, Patel R. Bronchopulmonary dysplasia is associated with reduced oral nitrate reductase activity in extremely preterm infants. Redox Biology 2020, 38: 101782. PMID: 33166868, PMCID: PMC7658701, DOI: 10.1016/j.redox.2020.101782.Peer-Reviewed Original ResearchConceptsWeeks post menstrual agePost menstrual ageBronchopulmonary dysplasiaPreterm infantsOral microbiomeBronchopulmonary dysplasia statusMorbidities of prematurityNO bioavailabilityBronchopulmonary dysplasia developmentNitric oxideAssociated with morbidityMenstrual ageNR activitySevere morbidityOral microbiotaPretermInfantsTherapeutic targetNitrate reductase activityPrematurityDysplasiaWeeksBioavailabilityNitrate reductaseDiseaseImportance of Dietary Phosphorus for Bone Metabolism and Healthy Aging
Serna J, Bergwitz C. Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging. Nutrients 2020, 12: 3001. PMID: 33007883, PMCID: PMC7599912, DOI: 10.3390/nu12103001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDietary phosphorusReduced bioavailabilityHealthy agingHigh dietary phosphorusSources of dietary phosphorusReduced longevityAbundance of phosphorusBone metabolismWestern dietPhosphorusTissue calcificationMetabolic changesEndocrine regulationBioavailabilityNormal amountsTissueCurrent knowledgeAbundanceDifferent tissuesExcessive lossOsteomalacia
2013
Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?
Lu L, Wu Y, Zuo L, Luo X, Large PJ. Intestinal microbiome and digoxin inactivation: meal plan for digoxin users? World Journal Of Microbiology And Biotechnology 2013, 30: 791-799. PMID: 24105082, DOI: 10.1007/s11274-013-1507-x.Peer-Reviewed Original ResearchConceptsDigoxin inactivationIntestinal microbiomeDigoxin usersArginine supplementsInactivation of digoxinBioavailability of digoxinHeart diseaseEpidemiological dataAnimal modelsMeal planTherapeutic agentsMetabolism of argininePotential interventionsDigoxinDiseaseDigoxin activityHuman diseasesRecent studiesMicrobiomeSupplementsBioavailabilityInactivationAgents
2010
Toward molecular design for hazard reduction—fundamental relationships between chemical properties and toxicity
Voutchkova A, Ferris L, Zimmerman J, Anastas P. Toward molecular design for hazard reduction—fundamental relationships between chemical properties and toxicity. Tetrahedron 2010, 66: 1031-1039. DOI: 10.1016/j.tet.2009.11.002.Peer-Reviewed Original ResearchPhysical/chemical propertiesCommercial chemicalsChemical propertiesMolecular designChemical compoundsToxics Release InventoryCompoundsQikPropChemicalsChemical characteristicsPhysical propertiesPropertiesExcretion characteristicsEPA Toxics Release InventoryAdsorptionToxicity endpointsHuman toxicityTRI chemicalsRelease InventoryBioavailabilityToxicity
1986
Effect of Supplemental Carbidopa on Bioavailability of l-Dopa.
Cedarbaum J, Kutt H, Dhar A, Watkins S, McDowell F. Effect of Supplemental Carbidopa on Bioavailability of l-Dopa. Clinical Neuropharmacology 1986, 9: 153. PMID: 3085927, DOI: 10.1097/00002826-198604000-00006.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply